That makes sense. The reality is that even if the combo with keytruda doesn’t improve anything except for maybe less side effects which I think we all believe it absolutely will improve circumstances merck will want to own it to extend their patent. You’re talking about 100’s of billions in revenues they get to continue to harvest. On a fire sale that’s a 10b buyout. So for me it makes no sense to be short something that could explode at any moment which again is the only thing that concerns me is do they know something we don’t know. (I don’t think they do). Biotechs with way less going on in phase 1 trials trade at multi billion dollar valuations and here we are at about 1b. I am puzzled?
Market Data 
Markets 
AI
